Introduction to Special Issue on Ocular Pathology and Drug Development

2021 ◽  
pp. 019262332098655
Author(s):  
Meg F. Ramos ◽  
Kenneth A. Schafer ◽  
Steven D. Sorden

Dysfunction of the visual system remains a leading cause of human disability worldwide. Preclinical studies are a key component of efforts to develop drugs and devices to ameliorate visual impairment. Although new opportunities for the delivery of targeted ocular therapeutics have been created, clinical success has been confounded by unique challenges of drug development for the eye. This Special Issue brings together a broad range of articles that augment our current understanding of the visual system and highlight methods for assessing ocular toxicity and some of the current challenges in ocular drug development. Topics addressed include the anatomy, developmental anatomy, and/or immunobiology of the visual system and associated lymphoid tissues; animal models; methods for assessing ocular toxicity; spontaneous background and procedure-related microscopic findings and common artifacts in histologic sections of ocular tissues; and novel ocular drug delivery systems.

Pharmaceutics ◽  
2019 ◽  
Vol 11 (7) ◽  
pp. 339 ◽  
Author(s):  
Maher ◽  
Casettari ◽  
Illum

Drug delivery systems that safely and consistently improve transport of poorly absorbed compounds across epithelial barriers are highly sought within the drug delivery field. The use of chemical permeation enhancers is one of the simplest and widely tested approaches to improve transmucosal permeability via oral, nasal, buccal, ocular and pulmonary routes. To date, only a small number of permeation enhancers have progressed to clinical trials, and only one product that includes a permeation enhancer has reached the pharmaceutical market. This editorial is an introduction to the special issue entitled Transmucosal Absorption Enhancers in the Drug Delivery Field (https://www.mdpi.com/journal/pharmaceutics/special_issues/transmucosal_absorption_enhancers). The guest editors outline the scope of the issue, reflect on the results and the conclusions of the 19 articles published in the issue and provide an outlook on the use of permeation enhancers in the drug delivery field.


1994 ◽  
Vol 8 (6) ◽  
pp. 373-378
Author(s):  
John L Wallace

Until the cause(s) of inflammatory bowel disease are identified, improvements in therapy will likely come from improved anti-inflammatory therapy or improved drug delivery systems. There are many potential targets for anti-inflammatory therapy, including the synthesis of specific inflammatory mediators. This review focuses on the potential for developing therapy aimed at three targets: nerves and neuropeptides; coagulation and thrombosis; and adhesion molecules. In each case, evidence is presented from clinical and/or experimental studies that supports the hypothesis that these are rational targets for anti-inflammatory drug development.


2005 ◽  
Vol 110 (1) ◽  
pp. 1-1
Author(s):  
Mitchell Brigell ◽  
Cun-Jian Dong ◽  
Serge Rosolen ◽  
Rad Tzekov

Sign in / Sign up

Export Citation Format

Share Document